Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764085 | 0.85 | ALDH1A1 (0.33) | ALDH1A1ESR1CYP3A4ESR2MAPK13 | |
| Butadiene SCHEMBL2766034 | 0.81 | — | — | |
| Butadiene SCHEMBL2765647 | 0.74 | MAPK13 (0.35) | ALDH1A1ESR1CYP3A4ESR2MAPK13 | |
| SCHEMBL27558772 | 0.71 | KMT2A (0.47) | ALDH1A1ESR1CYP3A4ESR2MAPK13 | |
| Butadiene SCHEMBL2765437 | 0.70 | KMT2A (0.47) | ALDH1A1CYP3A4 | |
| Butadiene SCHEMBL2766826 | 0.66 | — | — | |
| Butadiene SCHEMBL2766098 | 0.65 | CYP19A1 (0.34) | — | |
| SCHEMBL2765520 | 0.65 | ALDH1A1 (0.34) | ALDH1A1ESR1CYP3A4ESR2MAPK13 | |
| SCHEMBL2767056 | 0.64 | — | — | |
| SCHEMBL2764087 | 0.64 | ALDH1A1 (0.33) | ALDH1A1ESR1CYP3A4ESR2MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881802-B2 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | BRAP, MCM4, BOLA2; BOLA2B | ALDH1A1 3572/4885ESR1 2589/4885CYP3A4 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.